Table 2 List of the compounds targeting cAMP signaling
From: cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Category | Target | Antagonist | Agonist |
|---|---|---|---|
cAMP synthesis modulator | Adenylate cyclase | SQ22536; NB-001; ST034307; AC10065; MDL-12,330A | Forskolin |
sAC | Bithionol; Hexachlorophene; KH7; TDI-10229; TDI-11861; LRE1 | Â | |
Regulator of the cAMP sensor | PKA | aKT5720; H89; GSK299115A; GSK466317A; STAD 2; HA-1004; Daphnetin; MHY4571 | 6-Bnz-cAMP; 8-Bromo-cAMP; Sp-cAMPS; CW 008; Bucladesine |
bRp-8-Br-cAMP; Rp-cAMPS | Â | ||
cPKI(5-24)amide; PKI(5-22)amide; PKI-(6-22)-amide; PKI(14-22)amide; PKI(14-24)amide; Malantide | Â | ||
Pan-EPAC | ESI-08; ESI-09; HJC0197 | 8-CPT-Cyclic AMP; 8-pCPT-2'-O-Me-cAMP-AM | |
EPAC1 | AM-001; CE3F4; EPAC 5376753 | I942; SY009 | |
EPAC2 | AAK-399; AAD-026; MAY0132; HJC0350 | Â | |
Regulator of cAMP/cGMP hydrolysis | PDE3 | Cilostamide; Cilostazol; Olprinone; K134 | Â |
PDE4 | Rolipram; Eggmanone; Roflumilast; Cilomilast; Mufemilast; Zatolmilast; Oglemilast; Tetomilast; Lotamilast; ML-030; VI-1004; MR-L2; YM976; MK-0952; GSK356278; GSK256006; PF-06445974; D159687 | Â | |
PDE5 | Sildenafil; Vardenafil; Tadalafil; Avanafil; FR-229934 | Â |